The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2011

THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE,
RESPONSE TO FATIGUE TREATMENT, AND CYTOKINES AND
THEIR RECEPTORS, IN PATIENTS WITH ADVANCED CANCER
Sriram Yennu

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Oncology Commons

Recommended Citation
Yennu, Sriram, "THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE, RESPONSE TO FATIGUE
TREATMENT, AND CYTOKINES AND THEIR RECEPTORS, IN PATIENTS WITH ADVANCED CANCER" (2011).
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Dissertations and Theses (Open Access). 149.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/149

This Thesis (MS) is brought to you for free and open
access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE, RESPONSE
TO FATIGUE TREATMENT, AND CYTOKINES AND THEIR RECEPTORS, IN
PATIENTS WITH ADVANCED CANCER
by
Sriram Yennu, MD

APPROVED:
______________________________
Supervisory Professor: James M. Reuben, Ph.D
______________________________
Eduardo Bruera, M.D.
______________________________
Dave Balachandran, MD
______________________________
Alessandra Ferrajoli, M.D.
______________________________
Jonathan Trent, M.D, Ph.D.

APPROVED:

____________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE, RESPONSE
TO FATIGUE TREATMENT, AND CYTOKINES AND THEIR RECEPTORS, IN
PATIENTS WITH ADVANCED CANCER

A
THESIS
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
M. D. Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
For the Degree of
MASTER OF SCIENCE
by
Sriram Yennu, MD
Houston, Texas
May, 2011

Acknowledgements
I would like to thank my mentors and supervisors, Dr. Eduardo Bruera & Dr.
James Reuben, for their wisdom, support and guidance over the past 3 years. I
would also like to thank my graduate committee, Dr. Alessandra Ferrajoli, Dr.
Dave Balachandran, and Dr. Jonathan Trent for their advice regarding this study.
I would like to thank Dr. J Lynn Palmer and Dr. Saroj Vadhanraj for their
mentorship and key roles in designing the clinical trial. Finally, I am grateful to all
the patients enrolled onto this clinical study, who have in the process helped us
to gain a better understanding of new ways to improve the quality of life for
patients living with advanced cancer.

iii

Abstract
THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE, RESPONSE
TO FATIGUE TREATMENT, AND CYTOKINES AND THEIR RECEPTORS, IN
PATIENTS WITH ADVANCED CANCER
Publication No.________*
Sriram Yennu, MD
Supervisory Professor: James Reuben, MBA, PhD

Background: Inflammation is implicated in the development of cancer related
fatigue (CRF). However there is limited literature on the mediators of
inflammation (namely), cytokines and their receptors, associated with clinically
significant fatigue and response to treatment.
Methods: We reviewed 37 advanced cancer patients with fatigue (≥4/10), who
participated in two Randomized Controlled Trials, of anti-inflammatory agents
(Thalidomide and Dexamethasone) for CRF. Responders showed improvement
in FACIT-F subscale at the end of study (Day 15). Baseline patient
characteristics and symptoms were assessed by FACIT-F, ESAS; serum
cytokines [IL-1β and receptor antagonist (IL-1RA), IL-6, IL-6R, TNF-α and sTNFR1 and R2, IL-8, IL-10, IL-17] levels measured by Luminex. Data were analyzed
using principal component analysis (PCA) [reporting cumulative variance
(variance) for the first four components] to determine their association with
fatigue and response to treatment.
Results: Females were 54%. Mean (SD) was as follows for age, 61(14);
baseline FACIT (F) scores, 21.4(8.6); ESAS Fatigue item, 6.5(1.9); and FACIT-F
iv

change, 6.4(9.7); ESAS (fatigue) change, -2 (2.41). Baseline median in pg/mL for
IL-6, TNF-α, IL-1β were 31.9; 18.9; 0.55, respectively. Change in IL-6 negatively
correlated with change in FACIT-F scores (p=0.02). Baseline CRF (FACIT-F
score) was associated with IL-6, IL-6R and IL-17, Variance = 78% whereas IL-10,
IL-1RA, TNF-α and IL-1β were associated with improvement of CRF,
Variance=74%. Conversely, IL-6 and IL-8 were associated with no improvement
or worsening of CRF, Variance= 93%.
Conclusions: Change in IL-6 negatively correlated with change in FACIT-F
scores. IL-6, IL-6R and IL-17 are associated with CRF while IL-6 and IL-8 were
associated with no improvement of CRF. Further studies are warranted confirm
our findings.
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Chapter 1. Introduction
A. Background
A. 1. Fatigue in patients with cancer
Fatigue is the most common chronic and severe symptom associated with
cancer [1-3]. Fatigue is often the one symptom most likely to interfere with
physical and social activities. In cancer patients receiving cancer-related
treatment, the frequency of fatigue exceeds 75%. Among the cancer related
symptom, fatigue is the most severe symptom and has most profound influence
on patients’ quality of life [1]; more than 91% of affected patients reported that
fatigue interfered with their ability to lead normal lives.

Sixty-one percent of

patients reported that fatigue affected not only pain but their performance at
work; fatigued patients were absent an average of 4.2 days per month during and
immediately after treatment, because of fatigue [2]. Despite its effect on all
aspects of quality of life, cancer-related fatigue is under-treated or overlooked by
oncologists.

A. 2. Fatigue and advanced cancer
Previous research has shown that patients with advanced cancer develop severe
physical and psychosocial symptoms as a result of cancer and its treatments.
The frequency of cancer-related fatigue (CRF) varies from 60% to 90%. CRF is
more severe in advanced stages as compared to early disease stage [4]. CRF
can prevent these patients from receiving effective cancer therapy. Despite the
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prevalence of CRF, severity and effects on the quality of life of patients with
advanced lung cancer, there are limited treatment options available. Prior studies
have revealed that CRF has a multifactorial etiology in these patients [5]. Several
factors are significantly associated with CRF, including: anxiety, depression,
pain,

anorexia/cachexia,

drowsiness,

sleep

disturbances,

and

cognitive

functioning [6]. In recent years, several cytokines and other pro-inflammatory
mediators, produced by the host in response to the presence of cancer have
been found to be associated with symptoms such as fatigue, pain, cognitive
impairment, depression, cachexia, and sleep disorders [7-9]. The lack of effective
treatment is due to limited understanding of this complex pathophysiology and
inability to target the known complex mechanisms of CRF adequately.

A. 3. The Role of Cytokines and fatigue
Origination of the cytokines and general function: Cytokines are polypeptides
secreted by the immune cells (T –cells, macrophages) that mediate
communication between cells. The immune cells are activated in patients with
cancer by cancer, cancer complications and its treatment. The T-cell subsets
have a key role in the regulation of inflammatory responses. Immune cells via
inflammatory cytokines activate the transcription factor, Nuclear factor- Kappa B
[NF-κB], a critical regulator of pro-inflammatory responses. NF-κB can be found
in the cytoplasm of all cell types in its inactive form, associated with inhibitory
proteins known as inhibitors of NF-κB (IκB). NF-κB is also inactivated by the
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induction of IκB that prevents the nuclear translocation of NF-κB and the
subsequent transcription of inflammatory cytokines. [10].

Functions of inflammatory cytokines: Interleukin (IL)-1β is a pro-inflammatory
cytokine. It belongs to the gene family IL-1α and IL-1 receptor antagonist (IL1RA). These molecules bind to two receptors (type I and type II). Upon activation
by the ligand, the type I receptor complexes with accessory protein, which results
in signal transduction. IL-1 along with IL-6 and Tumor necrosis factor–alpha
(TNF-α) induce the synthesis of neurotransmitters such as serotonin,
Indoleamine 2,3 dioxygenase, p38 mitogen-activated protein kinase, dopamine
and glutamine [9]. These neurotransmitters are involved in modulation of
symptoms such as fatigue, depression which constitute the sickness behavior. In
addition these cytokines modulate pattern of secretion of hypothalamic -pituitary
adrenal axis [HPA] secretion that characterizes cancer related fatigue[ 9]. IL-6 is
secreted by T cells and macrophages. It acts as both pro- and anti-inflammatory
cytokine. IL-6 exhibits its action via a receptor complex consisting of specific IL-6
receptor and signal transducing subunit(gp130) by a process called transsignaling[11].
TNF-α is an inflammatory cytokine with primary action via two receptors TNF R1
and TNF R2. Upon contact with a ligand, the TNF receptors form trimers which
lead to conformational changes on the receptor leading to activarion of NF-kB,
MAPK and induction of death signaling pathways. In conjunction with IL-1β and
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IL-6, TNF-α modulate pattern of secretion of neurotransmitter and hypothalmicpituitary-adrenal axis[HPA] secretion as described earlier.
The interleukin (IL)-10 family of cytokines and the closely related interferon (IFN)
family of cytokines form the larger major histocompatabilty complex (Class II
cytokine family. IL-10 has strong anti-inflammatory properties by deactivation of
macrophages[12]. It downregulates the expression of Th1 cytokines such as
interferon –gamma, TNF-α, MHC class II antigens, and costimulatory molecules
on macrophages. It enhances B cell survival, proliferation, and antibody
production. Its action counter balances the action of elevated IL-1 and/ or TNF-α
to maintain homeostasis [13].

Downstream effects of various cytokines:
The biological functions of the cytokines are achieved by binding with high affinity
and specificity to cell surface receptors, thereby triggering signal transduction
cascades that regulate cellular function (e.g., activation, proliferation).

The cytokines effects are via tyrosine kinases such as Janus kinase(jaks). The
Jaks via its Phosphotyrosine- containing motifs bind to the receptors of signaling
proteins including Signal transducers and activators of transcription(STAT)
proteins. Upon binding the STAT proteins undergo phoshorylation and
dimerization. On transfer to nucleus the STAT proteins bind to the target gene
promoters and regulate transcription by binding to CBP protein or p300 coactivator molecules resulting in unwinding of DNA[10].
4

When an acute inflammatory response is triggered [e.g., Lipopolysaccaride and
endotoxin], the immune cells such as macrophages activate the nuclear NF-kB
which in turn lead to activation of the IL-1β, IL-6, and TNF-α[See Fig 1]. Finally
IL-6 inhibits IL-1β and TNF-α production not only by directly inhibiting the release
their synthesis and release [14], but also by stimulating the induction of IL-1β
receptor antagonist, IL-1RA, and sTNF-αRI [15]. This action counter balances
the action of elevated IL-1 and/ or TNF-α to maintain homeostasis [13].
Interleukins such as IL-6 are pleiotropic and exhibit overlapping function due to
sharing of common signal transduction pathways e.g., Functional receptor
complexes for interleukin-6 family of cytokines share gp130 as a component
critical for signal transduction [14].
Fig. 1. Interaction between various cytokines and hypothalamic –pituitary
adrenal axis [Illustration compiled based on the literature review from
Schindler et al., Vitkovic, Garg et al. and capuron et al.[9,10,13,and 14]
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The pleiotropic and overlap in function of various inflammatory cytokines due to
same cell distribution of their receptors and sharing common downstream
signaling pathways [10]. For example, following induction of external stimuli,
TNF-α and other cytokines such as IL-1β, IL-6, and TNF-α stimulates the
production of various inflammatory cytokines such as IL-1, IL-6, IL-8, IFN and
TGF-β. By the modulation of receptor expression of one cytokine by other or
interactions at the level of signal transduction, gene expression or
posttranslational level, the interactions of the cytokines can be synergistic (e.g.,
TNF-α -IL-1 interactions) or antagonistic (TNF-α and TGF-β) [16]

Prior studies have proposed the role of inflammatory cytokines such as IL-6 in
mediation of cancer related fatigue via various mechanisms including: (a) Neuroendocrine activation the hypothalamic-pituitary-adrenal (HPA) axis, leading to the
release of Growth hormone releasing hormone (GHRH) and corticotrophinreleasing hormone (CRH) by the hypothalamus [8,9]. Changes in the balance
between GHRH and CRH are the principal regulators of CRF. One mechanism
by which the cytokine exposure may influence HPA axis function is through
inhibitory effects on the receptor for glucocorticoids, cortisol, the end product of
HPA axis activation [9] (b) Effects on neurotransmission in the brain: Studies in
depression [9], have indicated that inflammatory cytokines effect symptoms such
as depression, fatigue by alteration synthesis and uptake of neurotransmitters
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such as serotonin, indoleamine 2,3 dioxygenase(IDO), p38 Mitogen activated
protein kinase (MAPK), dopamine, and glutamate[9]. One of the mechanism by
which inflammatory cytokines alters the secretion of neurotransmitters such as
serotonin is by enhancing the activity of serotonin transporter (SERT).

Studies on relationship between cancer-related-fatigue and cytokines:
Cytokines have been associated with the presence of tumors, co-morbidities
such as infections and the effects of cancer treatments including radiation
therapy and cytotoxic therapy [7-9]. In recent years, it has become evident that
many cytokines have powerful effects on the brain [9].

Animal models of

symptoms such as pain and cachexia, and clinical studies of immunotherapy in
which pro-inflammatory cytokines are administered to patients with various
cancers have provided important insights into the central effects of these agents
[9].

Sickness behavior [fatigue, depression, sleep alteration] is typically associated
with behavioral changes seen in laboratory animals suffering from microbial
infections [9,10].

IL-1β, IL-6, TNF-α were found to mediate sickness behavior

[9,10]. IL-1β, IL-6, TNF-α is known to cause the symptoms of sickness behavior
by it action in the brain, more specifically through the HPA axis [7,8,17,18].
Various studies have shown an association between severity of fatigue and
increase in cytokines. Greenberg et al [19] in a longitudinal study for 9 weeks in
15 cancer patients with prostate cancer receiving radiation therapy found a
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significant correlation of fatigue with IL-1B. Ahlberg et al. [20] in a longitudinal
study in 15 patients with uterine cancer receiving radiation therapy found a
significant negative correlation of fatigue with IL-6. Meyers et al.[21] in 54
patients with AML/MDS found significant correlations of IL-1RA and IL-6 with
severe fatigue. Rich et al. [18] in 80 advanced colorectal cancer patients found a
significantly positive association between fatigue and transforming growth factor
(TGF-α). Wang et al. [22] in 62 advanced lung cancer patients receiving radiation
therapy found serum IL-6 levels to be related to the increased mean levels of the
most severe symptoms (pain, fatigue, disturbed sleep, lack of appetite, sore
throat). Inagaki et al. [23] in 46 patients with advanced cancer found plasma IL-6
levels correlated with the fatigue.

A.4. Corticosteroids and fatigue
Dexamethasone is a synthetic glucocorticoid. It exhibits potent anti-inflammatory,
immunosuppressant activity with minimal mineralocorticoid properties. The action
of dexamethasone on cytokines such as IL-6, IL-1β, IL-8, IL-10 is by its effect on
transcription factor NF-κb which is instrumental in activation of multiple genes[2530]. Corticosteroids are hypothesized to decrease fatigue by decrease of the
cytokines IL-1, IL-6, TNF-α [17-23]. IL-1, IL-6, TNF-α are associated with the
causation of fatigue [7-9]. Table A. shows various studies in which corticosteroids
were used to manage cancer related fatigue.
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Table A. Corticosteroids (dosage and duration) in the management of cancer
related fatigue [29-42]

Author
Della Cuna 1989**
Vecht 1994**
Bruera et al 1995**
Popiela et al**
Italian group 2000**
Akira Inoue 2003**
JR Hardy 2001
Mercadante
Bruera 2004**

Number
of
patients
40
96
40
173
708
68
160
376
51

Treatment
Duration
(days)
56
28
14
56
5
6
22
26
7

Study
Drug*
MP
DM
MP
MP
DM
DM
DM
DM
DM

Equivalent
Dexamethasone
daily dose (mg)
23
4-16
6
23
8
8
12
4-16
20

*MP= Methylprednisolone, DM=Dexamethasone
** Randomized, double blind placebo controlled studies
A.5. Thalidomide and fatigue
Studies have identified several side effects of interferon therapy, including flu-like
symptoms such as somnolence and cancer related fatigue [9]. Sickness behavior
related to cancer treatment often manifests itself through the symptoms of CRF
[8-10]. It has been reported that cancer related symptoms such as fatigue,
depression are associated with an increase in IL-1, IL-6 and TNF-α [8,9]. Prior
studies show that Thalidomide improves symptoms contributing to fatigue
including sleep disturbance, anorexia and activity [5,32]. Thalidomide selectively
modulates the release of such as TNF-α(inhibits), IL-10(increased production)
and other cytokines and may potentially improve CRF [31,32].
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A.6. Theoretical construct[Fig.2.]
Previous research has shown that patients with cancer develop severe physical
and psychosocial symptoms [33,34]. The prevalence rates of the many different
symptoms reported by advanced cancer patients include fatigue 90%, followed
by pain 41%-76%, anorexia 85%, depression 33%-40%, anxiety 57%-68%,
nausea 24%-90%, constipation 65%, sedation/confusion 46%-60%, and dyspnea
12%-58% [33,34]. Various studies in patients with cancer showed that fatigue
usually occurs concurrently with other symptoms namely fatigue, anxiety,
depression and sleep disturbance and feeling of wellbeing which conform a
symptom cluster (Fatigue cluster) [35]. The brain is the ultimate organ where
symptoms are perceived [8,9,and17]. Recent studies showed that cancer
patients have a surge of inflammatory cytokines which play a predominant role in
the causation of fatigue and its cluster [7]. This change in cytokines occurs as a
result of complex interactions between the cancer and the host. It has been
noted that inflammatory cytokines can influence the stimulation of afferent nerves
at the periphery and some of the central synaptic activity at the dorsal horn and
in the brain cortex [9]. Also involved in the causation of fatigue is decreased
muscle function, tumor by products and the other symptoms that constitute the
cluster i.e., fatigue, anxiety, depression and sleep disturbance [35].
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Fig.2.Schematic diagram compiled based on the literature review of Dantzler et
al sickness behavior [8,9,17], illustrates the interactions between tumor, tumor
by-products, brain, nerves, cytokines, symptoms and anti-inflammatory agents
(thalidomide and dexamethasone).

B. Rationale: CRF is the most common distressing and severe symptom in
patients with cancer, impacting their quality of life. Unfortunately despite the
burden of CRF, there are no proven treatments for it in patients with advanced
cancer. The limited treatment options are due to limited understanding of its
complex pathophysiology. A number of studies have shown an association
between inflammatory markers and fatigue in cancer patients [7-17, 50]. In a
pooled analysis of eighteen studies that met the quality criteria, Schubert et al. [7]
found a significant positive correlation between CRF and IL-6, IL-1 receptor
antagonist (IL-1RA), and neopterin. However, there is limited published data to
11

show whether improvement in fatigue scores with targeted treatment results in
decrease in the elevated levels of inflammatory serum cytokines. As it may not
be possible to design a study to investigate the causative role of Inflammatory
cytokines for CRF due various confounders such as patient, disease and
treatment factors involved, a more feasible design is to investigate the
associations between change in inflammatory cytokines with treatment of antiinflammatory agent/s to treat fatigue. The ultimate goal is to find treatments for
CRF based on targets modulating the inflammatory markers.

The objective of this study was to obtain preliminary data to characterize the
inflammatory cytokines associated with fatigue in patients with advanced cancer
and assess the change inflammatory cytokines with change in fatigue scores with
fatigue treatment. The other exploratory objectives were to determine the
association of fatigue cluster with various inflammatory cytokines as the
manifestation of fatigue occurs concurrently with other symptoms such as
anxiety, depression, sleep, and feeling of well-being which collectively
constitutes, fatigue cluster. Fatigue cluster is believed to contribute to the
symptom burden in patients with advanced cancer which impact quality of life.
We also examined the effects of the anti-inflammatory agents (thalidomide, and
dexamethasone) on fatigue and the inflammatory cytokines. The preliminary data
from this study will be utilized to develop treatment strategies to alleviate fatigue
and improve quality of life as well as to help patients to tolerate treatment, in
general.
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C. The Hypothesis:
I

hypothesized

that

anti-inflammatory

agents

by

their

action

on

inflammatory cytokines are associated with change (decrease) in severity
of cancer related fatigue.

Specific Aims:
I planned to test this hypothesis and accomplish the objectives of this
project by performing the following specific aims:
a) To determine the mediators of inflammation (namely), cytokines (IL-1β,
IL-6, IL-8, IL-17, TNF-α and IL-10] and their soluble receptors, associated
with clinically significant fatigue s defined as fatigue score of ≥ 4/10 in a o10 scale.
b) To determine the mediators of inflammation (namely), cytokines (IL-1β,
IL-6, IL-8, IL-17, TNF-α & IL-10] and their receptors, associated response to
treatment.
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CHAPTER II. Research Design and Methods
We accessed the original data for this project from two prospective clinical trials:
protocol 2005-0816 Dexamethasone for symptom distress in advanced cancer
[NCT00489307] and The Effects of Thalidomide on Symptom Clusters, protocol
2005-0980 in patients with advanced cancer [NCT00379353]. We reviewed the
demographic information (such as age, gender, ethnicity, and cancer diagnoses),
Edmonton

Symptom

Assessment

System

(ESAS),

Memorial

delirium

assessment scale (MDAS), and Functional Assessment of Chronic Illness
Therapy-Fatigue (FACIT-F) scores at baseline and day 15. In both the studies,
patients who agreed to participate in the study were given a 14-day supply of
study medication.
We received approval from The University of Texas MD Anderson Cancer Center
Institutional Review Board for the present study and all patients provided written
informed consent at the time of their initial enrollments. Due diligence was taken
to protect the patients' confidentiality.
Performance Sites

Clinical setting
Patients with advanced cancer were recruited from The University of Texas MD
Anderson Cancer Center (MDACC; a comprehensive cancer center), Lyndon B.
Johnson General Hospital (LBJ: Harris county hospital) and Four Seasons
Hospice and Palliative care, Flat Rock, North Carolina(Four Seasons Hospice).
The physicians identified potentially eligible patients to participate in this study.
14

Research staff
The research staff in the Department of Palliative Care and Rehabilitation
Medicine includes a manager of clinical protocol administration, a research
nurse supervisor, three research nurses and a data coordinator. Our group
has conducted multiple clinical trials related to symptom management, quality
of life and communications between patients and physicians.

Patients Screening and Recruitment
Patients with advanced cancer were recruited from MDACC, LBJ and Four
Seasons Hospice. Inclusion criteria for the current study included the
following: a fatigue score 4 on a scale of 0–10 (0 = no fatigue, 10 = worst
possible fatigue) during the previous 24 hours; No clinical evidence of
cognitive failure as evidenced by MDAS score of ≥13 at baseline or normal
MMSE score (that is, a score ≥24); and a hemoglobin level ≥10 g/dL.
Exclusion criteria were of use of steroids (including dexamethasone,
Megestrol), thalidomide or lenalidomide, neutropenia, sepsis and/or acute,
chronic, or ongoing infections, pregnant and lactating women and all major
surgeries such as thoractomy, that requires wound healing within last 2
weeks.
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Patient rights and confidentiality
Patients were informed that refusing to participate in the study or electing to
terminate their participation will not affect their current treatment plan. The
patients were given a written and verbal description of the study during the
informed consent teaching interview. Guidelines regarding Institutional Review
Board, Human Rights Protection were strictly followed.

Study subjects signed an IRB-approved written informed consent form after
having the study explained to them in person by a physician. Patients were
assured that that lack of participation in the study would not bear a relationship to
their care for cancer or its symptoms. Circumstances of obtaining informed
consent were documented in patient medical records. Informed consent was
obtained in the language preference of the potential subject. When necessary,
professional translators, and not family members, were utilized to obtain written
informed consent.

We maintained confidentiality by assigning a study number to all study subjects.
Data collected was identified and tracked using this number. No names or other
identifying information were attached to the data collection.

16

Screening and accrual process is described in detail below:
a) The research nurse screened the electronic medical records of outpatient
center visits of all patients of collaborators for the patients meeting the
eligibility criteria.
b) The research nurse notified the Sriram Yennu MD, principal investigator
and the collaborator of the eligibility.
c) Eligible patients were approached by the research nurse to obtain
consent.
d) Consented patients were enrolled in the study. Reason for inability to
consent was documented in the screening log.
e) Weekly protocol meeting chaired by the PI, included the research nurse,
research manager, protocol manager, data coordinator to review the
screening, accrual, status of the patients on the study including adverse
events, serious adverse events, dropouts.
f) Annual review of the data was conducted by the data safety and
monitoring board at MD Anderson Cancer Center. The IRB conducted an
annual review of the protocol in regards to patient protection, accrual, and
adverse events. Department and Intuitional audits were performed in order
to ensure data quality.
Study treatment Plan
In the study, consenting eligible patients received study medication for 14 days.
Exam (including history including FACIT-F, ESAS and toxicity assessment were
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done at baseline, and Day 15 [± 3 days]. Serum cytokines (IL-1β, IL-6, IL-17,
TNF-α, IL-10, IL-8, and corresponding receptor levels), on baseline and Day 15
[± 3 days] were collected.

Study Medication strength, frequency:
•

The dose of dexamethasone was 8mg a day.

•

The dose of Thalidomide is 100mg a day.

Outcome Measures
1. Baseline demographics were collected from each patient and/or health records
just prior to initiation of study intervention, and included the following:
•

Demographics (date of birth, gender, race)

•

Cancer diagnosis (date of diagnosis, cancer type, treatments received)

•

Fatigue measures: Functional Assessment for Chronic Illness TherapyFatigue (FACIT-F) (see below for details)

Cytokine measures (See below for principles and Method in Appendix D):
Cytokines such as IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 (serum) and their
receptors have been reported to correlate with other symptoms such as fatigue
anorexia/cachexia, nausea, pain, depression, cognitive impairment and sleep
disorders in cancer patients.

In this study, we measured the levels of IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17
(serum) and their receptors at baseline, days15 [± 3 days]. The serum samples
18

were stored frozen for subsequent cytokine profile. Serum samples were
assayed. The cytokine profiles were correlated with the intensity of symptoms
and for the responsiveness or failure to respond to study medication. Proinflammatory cytokines IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 (serum) and their
receptors were measured in the serum of patients using commercially available
Luminex kit (Biosource Inc.). The Multiplex Bead Immunoassay was being used
to measure serum levels of IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 and their
receptors. Serum IL-10, IL-1β, IL-1RA, IL-6R, TNF-RI, TNF-R2 were also
analyzed using ELISA, as the data obtained were undetectable levels in majority
of study patients using Multiplex Bead Immunoassay.

Measure for Delirium:
•

Memorial Delirium Assessment Scale (MDAS) (Appendix A) is a 10 item
questionnaire validated in cancer patients for assessment of delirium (51). It
can be administered by a physician, a nurse or a research coordinator,
assigning a score between 0 and 30.

A score of >13 is suggestive of

delirium. This measure was used to assess the eligibility to the clinical study,
as patients with delirium are not eligible to participate in the study.
Fatigue Measures:
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
(Appendix B): The FACIT-F fatigue subscale has been used primarily in
cancer patients to measure fatigue (52). The subscale consists of 13 items.
Patients rate the intensity of fatigue and its related symptoms on a scale of 019

4, from 0 “not at all” to 4 “very much”. The scoring is 0-52 points, a higher
score (e.g., 48) indicates low intensity of fatigue and a low score (e.g., 11)
indicates severe fatigue. Test-retest reliability coefficients for the fatigue
subscale have ranged from 0.84-0.90. This scale has demonstrated strong
internal consistency (alpha=0.93-0.95). This assessment was performed at
baseline, and day 15.
The Edmonton Symptom Assessment System (ESAS) (Appendix C): This tool
was designed by our group to assist in the assessment of ten symptoms
common in cancer patients: pain, fatigue, nausea, depression, anxiety,
drowsiness, shortness of breath, appetite, sleep, and feelings of well-being
(53,54). The severity at the time of assessment of each symptom is rated
from 0 to 10 on a numerical scale, 0 meaning that symptom is absent and 10
meaning that it is of the worst possible severity. The instruments and
techniques are both valid and reliable in the assessment of the intensity of
symptoms in cancer populations. Symptom assessment was evaluated at
baseline, and day 15. Fatigue with other symptoms such as anxiety,
depression, sleep disturbance and feeling of wellbeing as assessed by ESAS
was used to calculate Fatigue cluster [FADSW] [35].

•

Methods for collection storage analysis and interpretation of cytokines
To study the effect(s) of study drug, levels of inflammatory cytokines
(interleukin-6 [IL-6], IL-8, IL-17,IL-10, IL-1β, and TNF-α), and cytokine
receptors (IL-6R, IL-1RA and soluble TNF-receptors (sTNF-R1, sTNF-R2)
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were measured at baseline, and day 15 of treatment in 45 patients who
consented for additional blood collections for optional correlative studies.

Collection and Storage of serum
Peripheral blood was drawn from all subjects and serum sample are stored as
per protocol [described in detail in Page 55, Appendix D and reference 55].

Principles and Methods of Multiplex Assay: Appendix: D
Statistical Analysis:
Distributions of data were examined by analyzing the data graphically. If the data
appeared to be non-normally distributed, then transformations to the data were
considered, or non-parametric equivalents of the parametric tests described in
the results below were used for analyses.

To determine the relationships between serum cytokines (IL-6, IL-8, and IL-10,
IL-1β, IL-17 and TNF-α), and cytokine receptors (IL-6R and soluble TNFreceptors (sTNF-R1, sTNF-R2), IL-1RA and fatigue at baseline and 14 days of
treatment, descriptive statistics for each variable were presented in tables. In
addition, we correlated cytokines and the fatigue [FACIT-F, ESAS fatigue item
]and fatigue cluster score using Spearman correlation coefficients as the data
was not normally distributed. We also reported the ratio of IL-6/IL-10 ratio as both
these

cytokines

constitute

the

predominant

pro-inflammatory

and

anti-

inflammatory response, their interaction may play a important role in the clinical
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manifestation of symptoms of cancer and its treatment such as fatigue and
fatigue clusters, the outcome of our study as evidenced in prior studies in
neonates, major surgeries, burns or trauma [56, 57].

We used principle component analysis (PCA) to determine which symptoms
cluster together to form a principle component and if other variables, such as
cytokines, will also load highly on individual factors. Our goal was to discover the
underlying,

unobservable

factors

(latent

factors)

associated

with

the

interrelationships of these variables. We included analyses of scores at two
points in time. Time one is at baseline, when all patients have not yet received
study medication; time two will be at day 15. For analyses at time two, we
performed PCA in whom we had observed improved fatigue (defined as atleast 1
point improvement in the FACIT-F fatigue scores) and those without improved
fatigue. Each PCA included the serum cytokines (interleukin-6 [IL-6], IL-8, and
IL-10, IL-1β, and TNF-α), and cytokine receptors [IL-6R and soluble TNFreceptors (sTNF-R1, sTNF-R11)], IL-1RA and the FACIT-F fatigue subscale
score.
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CHAPTER III. Results
The median age of the 45 patients was 62 years; the most common primary
cancers were gastrointestinal and lung. [Table 1]

Table 1.a. shows descriptive data of demographic characteristics, baseline
fatigue scores (FACIT-F, Fatigue subscale and ESAS, Fatigue item) and serum
inflammatory cytokines levels.
The median change of fatigue at the end of study (primary endpoint) was 6 points
(FACIT-F) and -2 points (ESAS-Fatigue item).
Table 1.b. shows that the serum levels of the control subjects was less than
fatigued advanced cancer patients. A Mann-Whitney U test determined the
difference between the control and fatigue patients of the study to be significant
for IL-6, TNF-α, IL-8, IL-17, and IL-1RA. However there was no difference in the
levels of IL-1β and IL-10.

Table 2 shows significant association between baseline fatigue as assessed by
FACIT-F and ESAS- fatigue item and fatigue cluster (Fatigue, anxiety,
depression, sleep disturbance and feeling of well-being). However no association
was found between baseline fatigue (FACIT-F) and baseline serum inflammatory
cytokines and receptors {IL-6, IL-8, and IL-10, IL-1β, and TNF-α), (IL-6R, IL-1RA
and soluble TNF-receptors (sTNF-R1, sTNF-R2)}.
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Table 3 shows significant association between baseline fatigue cluster (FADSW)
and baseline FACIT-F scores, serum cytokines IL-10, IL-6/IL-10 (proinflammatory and anti-inflammatory ratio).
Table 1. a. Patient characteristics(n=45)
Patient characteristics

Mean (SD)

Median

Age
Sex
Race

61(14)
Female 54%

62

White
Hispanic American
Asian American
African American

60%
6%
26%
8%

Primary cancer diagnosis (%)
Breast
Gastrointestinal
Genitourinary
Sarcoma
Lung/head and neck
Others a

3 (6%)
11(24%)
4 (8%)
6(13%)
10(22%)
11(24%)

a

brain, Lymphoma/myeloma/leukemia, gynecological,
no evidence of disease (NED), skin, unknown primary, melanoma.
* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster

Table 1.b. Baseline fatigue scores and change in fatigue scores after 14 days of treatment
Fatigue scale (n=45)
FACIT-F subscale
ESAS – Fatigue item
Fatigue cluster (FADSW)*
ESAS-F CHANGE
FACIT-F CHANGE

Mean(SD)
21.46(8.68)
6.55(1.99)
22.26(8.7)
-2(2.41)
6.4(9.73)

FACIT-F=Functional assessment of cancer illness therapy- fatigue
ESAS=Edmonton symptom assessment scale
Fatigue cluster= fatigue, anxiety, depression, sleep disturbance and feeling of well-being
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Median
22
7
21
-2
6

1 .c. Baseline cytokine and receptors levels in advanced cancer patients
with clinically significant fatigue(n=45

Baseline serum Cytokine
and Receptor levels(pg/ml)
IL-6
IL-1RA
TNF-α
IL-6R
IL-1 β
IL-8
IL-10
TNFR1
TNFR2
IL-17

Mean(SD)

Median

67.57(122)
725.7(542)
32.15(48.6)
14697(14780)
5.7(4.41)
403.7(1012.2)
11.77(15.5)
1511(973.7)
6914.6(6196)
82.5(165)

31.96
547
18.91
8812.5
0.55
82.16
4.9
1309
5445.6
22.42

Range

Table 1.d. Comparison of serum baseline cytokine levels with Normal controls
Median (pg/mL)
in fatigued
advanced
cancer patients

P-value*

45
45
45

Mean(SD)
(pg/mL) in
fatigued
advanced
cancer
patients
67.57(122)
32.15(48.6)
403.7(1012)

31.9
18.9
82.1

<0.001
Ψ
<0.001
Ψ
<0.001

45
39
34
38

82.5(165)
725.7(542),
5.7(4.41)
11.77(15.5)

22.4
547
0.55
4.9

0.03
Ψ
0.01
0.65
0.48

Serum
cytokines

N=
normal

Mean(SD)
(pg/mL)
in normal
controls

Median
(pg/mL)
in normal
controls

N=fatigued
advanced
cancer
patients

IL-6
TNF-α
IL-8

52
42
42

14.3(21)
14.6(50.9)
30.3(36.7)

7.08
5.9
16.7

IL-17
IL-1RA
IL-1β
IL-10

42
19
8
15

30(58)
265(139)
19.5(42.3)
50.5(137.
3)

7.2
231
3.4
2.9

* Mann-Whitney U test (two-tailed),
Ψ
A Mann-Whitney U test showed this difference to be significant.
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Ψ

Ψ

Table 2. Association of Baseline FACIT-F and Baseline Cytokines
Change in variables
with Treatment
FACIT-F
Fatigue(ESAS)
IL-6
IL-1RA
TNF-α
IL-6R
IL-1β
IL-8
IL-10
TNFR1
TNFR2
IL-17
IL6/IL10RATIO

r

P-value

-0.30
0.48
-0.20
-0.02
-0.05
-0.13
-0.14
0.14
0.34
-0.16
-0.26
0.13
-.47

0.04
0.001
0.18
0.86
0.74
0.38
0.40
0.34
0.02
0.28
0.07
0.40
0.002

*Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster

Table 3. Association of Baseline fatigue cluster and Baseline cytokines
Change in variables
with Treatment
Fatigue(ESAS)
Fatigue
cluster(FADSW*)
IL-6
IL-1RA
TNF-α
IL-6R
IL-1β
IL-8
IL-10
TNFR1
TNFR2
IL-17(L)
IL6/IL10 ratio

r

P-value

-0.49
-0.30

0.001
0.04

-0.05
0.04
0.07
0.07
0.21
-0.1
0.14
-0.04
0.05
-0.09
0.04

0.55
0.77
0.63
0.63
0.21
0.51
0.38
0.76
0.73
0.53
0.80
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Table 4. Association of change in FACIT-F and change in cytokines
Change in variables
with Treatment
Fatigue(ESAS)
IL-6
IL-1RA
TNF-α
IL-6R
IL-1β
IL-8
IL-10
TNFR1
TNFR2
IL-17(L)
IL6/IL10RATIO
ESAS-F CHANGE
FACIT-F CHANGE

r

P-value

-0.44
0.08
-0.24
0.01
-0.12
-0.26
-0.06
0.14
0.39
0.17
-0.15
-0.14
0.63
-0.396

0.002
0.56
0.88
0.90
0.52
0.15
0.67
0.59
0.07
0.24
0.34
0.38
0.0001
0.007

* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster

Table 5. Association of change in fatigue cluster and change in cytokines
Change in variables
with Treatment

r

P-value

Fatigue(ESAS)
FADSW*
IL-6
IL-1RA
TNF-α
IL-6R
IL-1β
IL-8
IL-10
TNFR1
TNFR2
IL-17
IL6/IL10RATIO

-0.44
-0.39
-0.34
0.14
-0.20
0.22
0.26
-0.24
0.16
-0.22
-0.19
-0.05
-0.14

0.002
0.007
0.02
0.37
0.17
0.13
0.16
0.37
0.34
0.16
0.33
0.78
0.40

* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster
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Table 4 shows change in fatigue was significantly associated with change in the
levels of serum IL-6 levels after treatment for 15 days. However none of the
change in serum levels of other inflammatory cytokines was associated with
change in fatigue after treatment.
Table 5 shows none of the change in serum levels of other inflammatory
cytokines was associated with change in fatigue cluster after treatment. TNFRI
was positively correlated with fatigue cluster with trends towards statistical
significance(r=0.39, p=0.07). Also interestingly the change in the fatigue scores
as assessed by FACIT-F is associated with change in fatigue cluster scores.
Exploratory principal component analysis reporting the 1st 4 principal
components (minimum .50 correlation) shows, baseline CRF (FACIT-F score)
was associated with IL-6, IL-6R and IL-17, Variance = 78% whereas IL-10, IL1RA, TNF-α and IL-1β were associated with improvement of CRF,
Variance=74%. Conversely, IL-6 and IL-8 were associated with no improvement
or worsening of CRF, Variance= 93%.

28

CHAPTER IV. Discussion:
The preliminary findings in this study show the effect of the key mediator for proinflammatory activity cytokine, IL-6 on CRF in patients with advanced cancer.
With treatment of CRF for 2 weeks, the change in IL-6 negatively correlated with
change in CRF [as assessed using a FACIT-F subscale scores] (p=0.02).

In our study, baseline CRF scores [FACIT-F subscale] in advanced cancer
patients were associated with serum levels of IL-6, IL-6R and IL-17 as measured
by principal component analysis. With treatment of CRF for 2 weeks, serum
levels of IL-10, IL-1RA, TNF-α and IL-1β were associated with improvement of
CRF. Conversely, serum levels of IL-6 and IL-8 were associated with no
improvement or worsening of CRF.
Findings in our study show increased serum levels of pro-inflammatory cytokines
with CRF at baseline. These findings are similar to other studies that have shown
increased serum levels of inflammatory markers in fatigued cancer patients
before treatment onset and during treatment such as chemotherapy and
radiotherapy [7, 8, and 50]. In this study we found increased levels of serum
cytokines IL-6, TNF-α, IL-8, IL-17, and IL-1RA in study patients compared to
control group [Table 1.d]. However there was no significant difference in the IL1β and IL-10 levels in advanced cancer patients compared to control group. This
may be due to a methodological issue with IL-1β assay, as most of the IL-1β is in
the bound form and adequate levels of the IL-1β cannot be detected. Therefore
IL-1RA may be a more reliable measure of serum IL-1 levels [7]. IL-10 is both an
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anti and pro-inflammatory cytokine and hence a variable association with fatigue
scores. Future larger sample studies with advanced cancer patients with no
fatigue as another cohort is required to validate these important findings.

However In this study there was no direct correlation between baseline fatigue
scores and baseline serum levels of cytokines. This may be (a) due to the fact
that they had moderate to severe fatigue prior to fatigue treatment, (b) lack of
data of serum cytokine levels in patients with advanced cancer with no fatigue.
(c) Small sample size, and (d) other interactions at baseline such as cancer type
and prior treatment received may have influence the association between fatigue
scores and cytokines.
Fatigue is one of the most common and distressing symptoms of cancer and its
treatment [1-4]. However there are no proven pharmacological treatments
available to date [58,59]. One main reason is lack of characterization and
understanding the pathophysiology of CRF [5,7]. As per the current NCCN
guidelines [60], most studies to date fail to identify the target mechanism. Based
on the results from our study, a larger study to investigate cytokines IL-6, IL-8, IL10, IL-1RA, TNF-α and IL-1β as one of the key target mechanism/common
denominator is warranted.
We observed a median of 6 point improvement in fatigue scores [FACIT-F
subscale] after 14 days of treatment. This improvement is above the minimal
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clinically important difference [MICD] in fatigue score [MICD using FACIT-F
scores is 3.5points] [61].

Fatigue as measured by FACIT-F fatigue subscale scores correlated with fatigue
measured ESAS Fatigue item and fatigue cluster (or overall fatigue burden)
(p<0.05). Moreover, the change in fatigue over time as measured by FACIT-F
correlated with the change fatigue measured ESAS Fatigue item and fatigue
cluster (or overall fatigue burden) (p≤0.007). These findings validate the findings
of a previous study showing the association between fatigue and fatigue clusters
[35].

The findings from this study are important as there are no published data
showing a change in the cytokines with change in CRF with fatigue treatment in
patients with advanced cancer [7-17]. A pilot work by Monk et al. [62] found
etanercept, a TNF inhibitor, treatment in solid cancer patients resulted in
improved fatigue. However the limitation of the study is small sample size and
lack of data and analysis showing the change in fatigue was due to change in
serum cytokines levels such as IL-1β, IL-6 or TNF-α.
Another important finding in the study is the association of fatigue cluster with
serum cytokines IL-10, IL-6/IL-10 (pro-inflammatory and anti-inflammatory ratio).
In addition, we found that a change in fatigue cluster was significantly associated
with change in the levels of serum TNF R1 receptor levels after treatment for 14
days. However the low significance levels (p=0.07) may be due to the small
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sample size. These findings provide preliminary hypothesis-generating data
regards to relationship between cytokines constituting the net inflammatory
burden and net fatigue burden (as defined in terms of fatigue cluster). Further
studies are needed to validate these findings which may result in finding
treatments to relieve the net fatigue burden and thus improve quality of life in
these distressed patients. Future studies should also consider combined anticytokine agents targeting various cytokines with complementary downstream
signaling pathways that modulate inflammation. This combined modality may
then reduce the possibility of redundancy, thereby a more sustained control of
inflammatory cytokines and possible effective improvement of CRF.
Limitations
This study has several limitations. First, the small sample size may have resulted
in lack of significant association between FACIT-F subscale scores and IL-6, IL8, IL-17, IL-10, IL-1β, TNF-α or their receptors at baseline. Second, as the
dexamethasone study is currently ongoing (121/125 accrued so far), we are
unable to provide the results of the correlation of the inflammatory cytokines with
the treatment (dexamethasone or thalidomide) and placebo. We were only able
to report the change in the inflammatory cytokines with or without improvement of
CRF in addition to the baseline characteristics of fatigue and cytokines in these
cohort of advanced cancer patients. However the process of design, methods
used for the assessment of symptoms and analysis of cytokines were strictly
followed as per protocol. On conclusion of the dexamethasone trial I will be able
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to analyze the effect of anti-cytokine agents (dexamethasone or thalidomide) on
cytokines and fatigue as compared to placebo and publish the results of the data
of all study patients. Thirdly, fluctuation of cytokine levels and intensity of fatigue
is common in cancer patients. As only one assessment of fatigue and single
blood sample was performed at a time point in our study, future studies could
consider use of multiple blood sampling at different times of the day as well as
multiple daily assessments of fatigue [7].

Conclusion:
Based on the preliminary analyses CRF score and serum inflammatory cytokines
of advanced cancer patients, the change in IL-6 negatively correlated with
change in CRF scores after fatigue treatment. With treatment of CRF for 2
weeks, serum levels of IL-10, IL-1RA, TNF-α and IL-1β were associated with
improvement of CRF. Conversely, serum levels of IL-6 and IL-8 were associated
with no improvement or worsening of CRF. These findings provide important
preliminary data regards to the role of various inflammatory cytokines have on
causation of CRF. Future studies are warranted to validate these findings using a
larger sample so as to develop treatment strategies that target specific cytokines
that are known to mediate the causation of CRF.
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Appendix: A
Memorial Delirium Assessment Scale (MDAS)
INSTRUCTIONS: Rate the severity of the following symptoms of delirium based
on current interaction with subject
Or assessment of his/her behavior or experience over past several hours (as
indicated in each time.)
ITEM 1-REDUCED LEVEL OF CONSCIOUSNESS (AWARENESS): Rate the
patient’s current awareness of and
Interaction with the environment (interviewer, other people/objects in the room;
for example; ask patients to
Describe their surroundings).
0: none (patient spontaneously fully aware of environment and interacts
appropriately)
1: mild
(patient is unaware of some elements in the environment, or not
spontaneously interacting
appropriately with the interviewer; becomes fully aware and
appropriately interactive when
prodded strongly; interview is prolonged but no seriously
disrupted)
2: moderate
(patient is unaware of some or all elements in the
environment, or not spontaneously interacting
with the interviewer; becomes in completely aware and
inappropriately interactive when prodded
strongly: interview is prolonged but not seriously disrupted)
3: severe (patient is unaware of all elements in the environment with no
spontaneous interaction of
awareness of the interviewer, so that the interview is difficulty-toimpossible even with maximal
prodding
ITEM 2-DISORENTATION: Rate current state by asking the following 10
orientation items: date, month day, year,
Season, floor, name of hospital, city, state, and country.
0: none (patient knows 9-10 items)
1: mild (patient knows 7-8 items)
2: moderate
(patient knows 5-6 items)
3: severe (patient know no more than 1 item)
ITEM 3-SHORT-TERM MEMORY IMPAIRMENT: Rate current state by using
repetition and delayed recall of 3 words [patient must immediately repeat and
recall words 5 min later after an intervening task. Use alternate sets of 3 words
for successive evaluations (for example, apple, table, tomorrow, sky, cigar,
justice)].
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0: none (all 3 words repeated and recalled)
1: mild
(all 3 repeated, patient fails to recall 1)
2: moderate
(all 3 repeated, patient fails to recall 23)
3: severe (patient fails to repeat 1 or more words)
ITEM 4-IMPAIRED DIGIT SPAN: Rate current performance by asking subjects to
repeat first 3, 4, then 5 digits
Forward and then 3, then 4 backwards; continue to the next step only if patient
succeeds at the previous one.
0: none (patient can do at least 5 numbers forward and 4 backward)
1: mild
(patient can do at least 5 numbers forward and 3 backward)
2: moderate
(patient can do 4-5 numbers forward, cannot do 3 backward)
3: severe (patient can no more than 3 numbers forward)
ITEM 5-REDUCED ABILITY TO MAINTAIN AND SHIFT ATTENTION: As
indicated during the interview by
Questions needing to be rephrased and/or repeated because patient’s
attention wanders, patient loses track,
Patient is distracted by outside stimuli or over-absorbed in a task.
0: none (none of the above, patient maintains and shifts attention normally)
1: mild
(above attentional problems occur once or twice without prolonging
the interviews)
2: moderate
(above attentional problems occur often, prolonging the
interview without seriously disrupting it)
3: severe (above attentional problems occur constantly, disrupting and
making the interview
difficult-to-impossible
ITEM 6-DISORGANIZED THINKING: As indicated during the interview by
rambling irrelevant, or incoherent
Speech, or by tangential, circumstantial, or faculty reasoning. Ask patient
a some a somewhat complex question
(for example, “Describe your
current medical condition”).
0: none (patient’s speech is coherent and goal-directed)
1: mild
(patient’s speech is slightly difficult to follow: responses to
questions are slightly off target but not
so much as to prolong the interview)
2: moderate
(disorganized thoughts or speech are clearly present, such
that interview is prolonged but not
disrupted)
3: severe (examination is very difficult or impossible due to disorganized
thinking or speech)
Appendix 1
Memorial Delirium Assessment Scale (MDAS)o 1996
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ITEM 7-PERCEPTUAL DISTURBANCE: Misperceptions, illusions, hallucinations
inferred from inappropriate
behavior during the interview or admitted by subject, as well as those elicited
from nurse/family/chart accounts of
the past several hours or of the time since last examination:
0: none (no misperceptions, illus9ions, or hallucinations)
1: mild
(misperceptions or illusions related to sleep, fleeting hallucinations
on 1-2 occasions without
inappropriate behavior)
2: moderate
(hallucinations or frequent illusions on several occasions
with minimal inappropriate behavior
that does not disrupt the interview)
3: severe (frequent or intense illusions or hallucinations with persistent
inappropriate behavior that
disrupts the interview or interferes with medical care)
ITEM 8-DELUSIONS: Rate decisions inferred from inappropriate behavior
during the interview on admitted by the patient, as well as delusions elicited
from nurse/family/chart accounts of the past several hours of the time
Since the previous examination.
0: none (no evidence of misinterpretations on delusions)
1: mild
(misinterpretation or suspiciousness without clear delusional ideas
or inappropriate behavior)
marginally disrupt the interview of interfere with medical
care)
2 moderate
(delusions admitted by the patient or evidenced by his/her
behavior that do not or only
marginally disrupt the interview or interfere with medical
care)
3: severe (persistent and/or intense delusions resulting in inappropriate
behavior, disrupting the interview
or seriously interfering with medical care)
ITEM 9-DECREASED OR INCREASED PSYCHOMOTOR ACTIVITY: Rate
activity over past several hours, as well as activity during interview by circling
(a) hypoactive, (b) hyperactive, or (c) elements of both present.
0: none (normal psychomotor activity)
a b c 1: mild
(hypoactivity is barely noticeable , expressed as lightly
slowing of movement. Hyperactive is
barely noticeable or appears as simple restlessness.
abc
(Hypoactivity is undeniable, with marked reduction in the
number of movements or marked
2: moderate
slowness of movement, subject rarely spontaneously moves
or speaks. Hyperactivity is
undeniable, subject moves almost constantly; in both cases,
exam is prolonged as a
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consequence.)
a b c 3: severe (Hypoactivity is severe, patient does not move or speak
without prodding or is catatonic.
Hyperactivity is severe, patient is constantly moving,
overreacts to stimuli, requires surveillance
and/or restraint, getting through the exam is difficult or
impossible .)
ITEM 10-SLEEP-WAKE CYCLE DISTURBANCE (DIORDER OF AROUSAL):
Rate patient’s ability to either sleep
Or stay awake at the appropriate times. Utilize direct observation during the
interview, as well as reports from
Nurses, family, patient, or charts describing sleep-wake cycle disturbance over
the past several hours or since last
Examination. Use observations of the previous night for morning evaluations
only.
0: none (at night sleeps well; during the day, has no trouble staying awake)
1: mild
(mild deviation from appropriate sleepfulness and wakefulness
states at night, difficulty falling
asleep or transient night awakenings, needs medication to sleep
well; during the day, reports
periods of drowsiness or, during the interview, is drowsy but can
easily awaken him/
herself)
2: moderate
(moderate deviations from appropriate sleepfulness and
wakefulness states at night, repeated and
prolonged night awakening, during the day, reports of frequent and
prolonged napping or,
during the interview, can only be roused to complete wakefulness
by strong stimuli)
3: severe (severe deviations from appropriate sleepfulness and wakefulness
states, at night, sleeplessness
during the day, patient spends most of the time sleeping or
during the interview cannot be
roused to full wakefulness by any stimuli)
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Appendix: D
METHODS OF CYTOKINE ASSESSMENT
Serum preparation
Collect whole blood in a preservative-free and anticoagulant free (red top)
Vacutainer tube (Becton-Dickinson). After collection of the whole blood, allow the
blood to clot by leaving it undisturbed at room temperature. This usually takes
15-30 minutes. Remove the clot by centrifuging at 1,000-2,000 x g for 10 minutes
in a refrigerated centrifuge. The resulting serum supernatant is immediately
transferred into a clean polypropylene tube using a Pasteur pipette. The samples
should be maintained at 2-8°C while handling. If the serum is not analyzed
immediately, the serum will be apportioned into 0.5 mL aliquots in a Nunc
cryovial and stored and transported at –20°C or lower. It is important to avoid
freeze/thaw cycles because this is detrimental to many serum components.
Samples that are hemolyzed, icteric, or lipemic can invalidate certain tests, and
may need to be re-collected. All serum samples were frozen at –80 °C until ready to
assay them in batch. The frozen serum samples were be rapidly thawed and
brought to room temperature just before they are to be assayed for cytokines. .

Determination of Cytokines by Luminex Multiplex Cytometric
Bead Array Assay
Principles of the Method
•

•

•

•

•

Beads of defined spectral properties conjugated to analyte specific
capture antibodies and samples (including standards of known analyte
concentration, control specimens, and unknowns) are pipetted into the
wells of a filter bottom micro titer well plate and incubated for 2 hours.
During this first incubation, analytes bind to the capture antibodies on
the beads. After washing the beads, analyte-specific biotinylated
detector antibodies are added and incubated with the beads for 1 hour.
During the second incubation, the analyte-specific biotinylated detector
antibodies recognize their epitopes and bind to the appropriate
immobilized analytes. After removal of excess biotinylated detector
antibodies, streptavidin conjugated to the fluorescent protein, RPhycoerythrin (Streptavidin-RPE), is added and incubated for 30
minutes.
During this final incubation, the Streptavidin-RPE binds to the
biotinylated detector antibodies associated with the immune complexes
on the beads, forming a four-member solid phase sandwich.
After washing to remove unbound Streptavidin-RPE, the beads are
analyzed with the Luminex 100™ instrument. By monitoring the
spectral properties of the beads and the amount of associated R-
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Phycoerythrin (RPE) fluorescence, the concentration of one or more
analytes can be determined.

Preparation of Standard
Reconstitute the protein standard within one hour of performing the assay. All
standards are calibrated to NIBSC preparations, when available. Additional
standards are available from BioSource, Carlsbad, CA. The standard included in
the kit is provided as a premixed set of related markers. The concentrations of
the protein components of the standard are indicated on the information sheet
included in the kit. Standard dilutions may be performed in glass or plastic tubes.
When using serum or plasma samples, reconstitute the standard with Assay
Diluent provided. Protein standards may be analyzed alone, or may be combined
with other protein standards for higher levels of multiplexing.
Assay Procedure (Figure A, adapted from

Fig A. Multiplex Assay Procedures(Adapted from
Biosource, Invitrogenm Carlsba, CA)

BioSource
, Invitrogen, Carlsbad, CA )

1. Pre-wet the wells designated for the
assay. Pipette 0.2 mL of Working
Wash Solution into designated wells.
Wait 15 to 30 seconds then aspirate
the Working Wash Solution from the
wells using the vacuum manifold.
Wells not used during the assay
should be kept dry for future use. An
adhesive plate cover may be used to
seal the unused wells.
2. Vortex the diluted bead solution for 30
seconds, then sonicate for at least 30
seconds immediately prior to use in
the assay.
3. Pipette 25 µL of the diluted bead
solution into each well. Once the
beads are added to the plate, keep the
plate shielded from light.
4. Add 0.2 mL Working Wash Solution to
the wells. Allow the beads to soak for
15 to 30 seconds, and then remove
the Working Wash Solution from the
wells by aspiration with the vacuum
manifold. Repeat this washing step. Blot residual liquid from the bottom of the
plate on clean paper towels.
5. Pipette 50 µL Incubation Buffer into each well.
6. To the wells designated for the standard curve, pipette 100 µL of appropriate
standard dilution.
7. To the wells designated for the sample, pipette 50 µL Assay Diluent followed by
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50 µL sample.
8. Incubate the plate for 2 hours at room temperature on an orbital shaker.
Shaking should be sufficient to keep beads suspended during the incubation
(500-600 rpm).
9. Ten to fifteen minutes prior to the end of this incubation, prepare the
biotinylated detector antibody in accordance with instruction.
10. After the 2 hour capture bead incubation, remove the liquid from the wells by
aspiration with the vacuum manifold. Add 0.2 mL Working Wash Solution to the
wells. Allow the beads to soak for 15 to 30 seconds, then aspirate with the
vacuum manifold. Repeat this washing step. Blot residual liquid from the bottom
of the plate on clean paper towels.
11. Add 100 µL of 1x stock, diluted Biotinylated Detector Antibody to each well and
incubate the plate for 1 hour at room temperature on an orbital shaker. Shaking
should be sufficient to keep the beads suspended during incubation (500-600
rpm).
12. Ten to fifteen minutes prior to the end of the detector incubation step, prepare
the Streptavidin-RPE in accordance with instruction.
13. Remove the liquid from the wells by aspiration with the vacuum manifold. Add
0.2 mL Working Wash Solution to the wells. Allow the beads to soak for 15 to
30 seconds, then aspirate with the vacuum manifold. Repeat this washing step.
Blot residual liquid from the bottom of the plate on paper towels.
14. Add 100 µL of 1x stock, diluted Streptavidin-RPE to each well and incubate the
plate for 30 minutes at room temperature on an orbital shaker. Shaking should
be sufficient to keep the beads suspended during incubation (500-600 rpm).
15. Prepare the Luminex 100 instrument during this incubation step.
16. Remove the liquid from the wells by aspiration with the vacuum manifold. Wash
the beads by adding 0.2 mL Working Wash Solution to the wells; allow the
beads to soak for 10 seconds, then aspirate with the vacuum manifold. Repeat
this washing step two additional times for a total of 3 washes.
17. Add 100 µL of Working Wash Solution to each well. Shake the plates on an
orbital shaker (500-600 rpm) for 2-3 minutes to resuspend the beads. If the
plates cannot be read on the day of the assay, they may be covered and stored
in a dark location overnight at 2 °C to 8 °C for reading the following day without
significant loss of fluorescent intensity. Aspirate Working Wash Solution from
stored plates and add 100 µL fresh Working Wash Solution. Place the plate on
an orbital shaker 2-3 minutes prior to analysis.
18. Uncover the plate; insert the plate into the XY platform of the Luminex 100
instrument, and analyze the samples.
19. Determine the concentration of samples from the standard curve using curvefitting software. The four-parameter algorithm usually provides the best fit.
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Measurement of Serum Cytokines by ELISA
Principle of the assay
•

•
•
•

•

This assay employs the quantitative sandwich enzyme immunoassay
technique. Each well of the 96 wells of a micro titer well plate is pre-coated
with a monoclonal antibody specific for a cytokine.
Standards and samples are pipetted into the wells and the immobilized
antibody binds the particular cytokine.
After washing away any unbound substances, an enzyme-linked
monoclonal antibody specific for a cytokine is added to the wells.
Following a wash to remove any unbound antibody-enzyme reagent, a
substrate solution is added to the wells and color develops in proportion to
the amount of cytokine bound in the initial step.
The color development is stopped and the intensity of the color is
measured. The concentration of the analyte is directly proportional to the
intensity of the color of the enzymatic reaction.

Assay procedure
1. Warm up all reagents, working standards, and samples to room
temperature.
2. Add 50 µL of Assay Diluent to each well.
3. Add 200 µL of Standard, control, or sample per well. Cover with the
adhesive strip provided with the kit. Incubate for 2 hours at room
temperature.
4. Aspirate each well and wash, repeating the process three times for a total
of four washes. Wash each well by filling each well with Wash Buffer (400
µL) using a squirt bottle, manifold dispenser or automatic washer.
Complete removal of liquid at each step is essential to good performance.
After the last wash, remove any remaining Wash Buffer by aspirating or
decanting. Invert the plate and blot it against clean paper towels.
5. Add 200 µL of Conjugate to each well. Cover with a new adhesive strip.
6. Incubate for 2 hours at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add 200 µL of Substrate Solution to each well. Protect from light. Incubate
for 30 minutes at room temperature.
9. Add 50 µL of Stop Solution to each well. If color change does not appear
uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a
microplate reader set to 450 nm. If wavelength correction is available, set
to 540 nm or 570 nm. If wavelength correction is not available; subtract
readings at 540 nm or 570 nm from the readings at 450 nm. This
subtraction will correct for optical imperfections in the plate. Readings
made directly at 450 nm without correction may be higher and less
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accurate.
11. Create a standard curve by reducing the data using computer software
capable of generating a four parameter logistic (4-PL) curve-fit. As an
alternative, a standard curve will be constructed by plotting the mean
absorbance for each standard on the y-axis against the concentration on
the x-axis and drawing a best-fit curve through the points on the graph.
Plotting the log of cytokine concentrations versus the log of optical density
(OD) may linearize the data, and the best-fit line can be determined by
regression analysis. This procedure produces an adequate but less
precise fit of the data. If samples have been diluted, concentrations read
from the standard curve will be multiplied by the dilution factor.
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Appendix: E
Study consent
INFORMED CONSENT/AUTHORIZATION FOR PARTICIPATION IN
RESEARCH WITH OPTIONAL PROCEDURES
The Effect of Dexamethasone on Symptoms in Patients with Advanced
Cancer
2005-0816
Study Chair: Sriram Yennurajalingam
1
.
Participant’s Name

Medical Record Number

You are being asked to take part in this clinical research study at The
University of Texas M. D. Anderson Cancer Center ("M. D. Anderson").
This consent form explains why this research study is being done and
what your role will be if you choose to take part. This form also
describes the possible risks connected with being in this study. After
reviewing this information with the person responsible for your
enrollment, you should know enough to be able to make an informed
decision on whether you want to take part in the study.
You are being asked to take part in this study because you have
advanced cancer and are experiencing weight loss, fatigue, pain,
nausea, loss of appetite, sleep problems, and/or depression.
DESCRIPTION OF RESEARCH
2. PURPOSE OF STUDY
The goal of this clinical research study is to learn if dexamethasone
can help to control symptoms such as fatigue, pain, nausea, weight
loss, loss of appetite, sleep problems, and/or depression in patients
with advanced cancer.
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Optional Procedures: You will be asked to allow blood to be drawn
for tests to study how levels of certain proteins in your blood (called
cytokines), white blood cells (called monocytes) and cell receptors for
these proteins are affected by taking dexamethasone and how this
may change the symptoms you have.
You are being asked to complete a questionnaire on the quality of your
sleep.
You are being asked to give saliva samples to check your level of
cortisol. Cortisol is a hormone that may be affected by sleep pattern
changes.
3. DESCRIPTION OF STUDY
Dexamethasone decreases inflammation and also suppresses the
immune system.
Before you can start treatment on this study, you will have what are
called "screening tests". These tests will help the doctor decide if you
are eligible to take part in this study. You will answer questions about
your diagnosis, the medication you are taking, and the symptoms you
are having (for example, pain, fatigue, nausea, appetite problems,
sleep problems, depression, and your overall feeling of well-being).
Blood (about 1 tablespoon) will be drawn to measure protein levels.
The blood work for protein levels and iron are screening tests and
done at baseline to see if you have too little iron in your blood. Blood
will be drawn to test hemoglobin levels (about 1 tablespoon). It will
take about 30 minutes to complete all the screening tests.
If you are found to be eligible for this study, you will be randomly
assigned (as in the toss of a coin) to receive either dexamethasone or
a placebo by mouth in the morning and at night with food every day for
14 days. A placebo is a substance that looks like the study drug but
which has no active ingredients. You will have an equal chance of
being placed in either of the 2 groups. You, the medical staff, and
researchers will not know to which group you have been assigned.
Beginning on Day 15 [± 3 days], regardless of if you were assigned to
the dexamethasone or placebo group during the first 14 days, you will
begin receiving the dexamethasone. On Days 15-21, you will receive
dexamethasone 2 times a day. On Days 22-28 you will continue to
take dexamethasone 2 times a day, but it will be at a lower dose level.
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If you develop intolerable side effects while on this study, the
medication will be stopped and you will be removed from the study.
You will be asked to return to the outpatient clinic on Days 8 [± 3 days],
15 [± 3 days] , 22 [± 3 days], and 29 [± 3 days] to answer a
questionnaire about your cancer diagnosis, the medication you are
taking, and the symptoms you are having (for example, pain, fatigue,
nausea, appetite problems, sleep problems, depression, and your
overall sense of well-being). The questionnaire will take
approximately 30 minutes to complete. Blood (about 1 tablespoon)
will be drawn to measure protein levels and to check the iron level in
your blood. If you are unable to return to the clinic on days 8, 15, 22,
or 29; the assessments will be done by the research nurse by phone;
the blood work will not be done.
You will be considered off-study on Day 29 [ ± 3 days]. All study
patients will have a 2 week follow-up on day 43 [± 3 days] after study
drug has been discontinued, for safety and toxicity assessments. If
you are unable to return to the clinic on day 43, the research nurse will
do the safety and toxicity assessment by phone.
This is an investigational study. Dexamethasone has been
approved by the FDA and is a commercially available drug. It is FDA
approved at this dose level. Its use in this study, for this purpose, is
investigational. Dexamethasone will be provided free of charge during
this study up to Day 29. It can continue to be prescribed to you by
your primary doctor after that time, if needed, but you and/or your
insurance provider will then be responsible for the cost of the
dexamethasone. About 125 patients will take part in this study. Up to
75 will be enrolled at M. D. Anderson. The other sites participating in
this study are Lyndon Baines Johnson [LBJ] breast oncology clinic
Houston Texas, and Four Seasons Hospice in Flat Rock, North
Carolina.
Optional Procedures: If you agree, extra blood (about 1 tablespoon
each time) will be drawn and used to study the effect dexamethasone
has on proteins in your blood (called cytokines), white blood cells
(called monocytes) and cell receptors for these proteins and how
changes in these proteins affect the symptoms you have. This blood
will be drawn on Days 8, 15, 22, and 29. If you are unable to return to
the clinic the blood work will not be done.
If you agree, you will complete a questionnaire at the beginning of the
study and on Day 15. The questionnaire asks questions about sleep
quality, including bed time, length of time to fall asleep, and symptoms.
It takes about 5 minutes to complete.
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You will also be asked to provide a saliva sample to test for cortisol
levels at the beginning of the study and on Day 15. You will be given
detailed instructions on how to collect the saliva samples.
There will be no cost to you for taking part in the optional procedures.
You do not have to agree to take part in the optional procedures in
order to receive treatment on this study.
4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS
While on this study, you are at risk for the side effects listed in this
form. You should discuss these with the study doctor or your regular
doctor. The known side effects are listed in this form, but they will vary
from person to person. Many side effects go away shortly after the
study drug is stopped, but in some cases side effects may be serious,
long lasting, and/or permanent and may even cause death.
Dexamethasone Side Effects
It is not known how often the side effects of dexamethasone may
occur.
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rregular heartbeat
slow heartbeat
cardiac arrest (sudden
stopping of the heart)
enlarged heart
heart failure
swelling
high blood pressure
tearing of the walls of the
heart
fainting
shock
depression
unstable emotions
euphoria (abnormal
feelings of great happiness
or well-being)
headache
increased pressure
between the skull and brain
(possible headache)
difficulty sleeping
weakness
mood swings
nerve inflammation
personality changes
psychotic disorders
seizures
dizziness
acne
skin inflammation
hair loss
tissue swelling
bruising
dry skin
skin redness
lightening and/or darkening
of the skin
fragile skin
excessive/increased hair
growth
spots under the skin
skin rash
skin thinning
skin tests (such as for TB)
may not be accurate

decreased function of
the adrenal glands,
which could affect the
body's ability to control
blood pressure and/or
react to stress
increased hormone
production (possible
difficulty managing
weight and muscle
weakness)
diabetes
abnormal blood sugar
test (also known as
"pre-diabetes")
stunted growth in
children
high blood sugar
(possible diabetes)
low blood levels of
potassium (possibly
due to fluid loss)
low levels of nitrogen
abnormal hormone
production (possible
fatigue, difficulty
managing weight,
and/or problems
fighting infection)
abnormal breakdown of
proteins
high blood levels of
sodium (possible
weakness and/or
swelling)
bleeding in the
digestive system
abdominal swelling
anal itching
increased appetite
hole in the stomach
and/or intestines, which
may cause the contents
to leak
nausea
inflammation of the
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changes to the
menstrual cycle
abnormal sperm
development
blood clot blocking a
blood vessel (possible
stroke)
blood vessel
inflammation (possible
fever and/or fatigue)
inflammation of a vein
caused by blood clot
enlarged liver
abnormal liver tests
(possible liver damage)
joint disease and/or
pain
death of bone tissue
broken bones
loss of muscle mass
muscle disease that
causes weakness
nervous system
disease (possible pain
and/or weakness)
decreased bone
density (possible
fractures)
tickling/tingling
sensation
rip in a tendon
abnormal fat deposit
collapse of spinal
bones
cataracts (clouding of
the lens of the eye)
bulging eye
increased pressure in
the eye (possible loss
of vision)
high levels of sugar in
the urine
build-up of fluid in the
lungs
allergic reaction
(possibly severe)

stretch marks
hives
sweating
decrease in carbohydrate
tolerance

pancreas (possible
abdominal pain)
sore in the stomach,
small intestine, and/or
esophagus
weight gain

poor blood supply and
death of tissue
hiccups
infection
moon face
new occurrence of
cancer
malignant skin lesions
wound healing
problems

Questionnaires may contain questions that are sensitive in nature.
You may refuse to answer any question that makes you feel
uncomfortable. If you have concerns after completing the
questionnaire, you are encouraged to contact your doctor or the study
chair.
Blood draws may cause pain, bleeding, and/or bruising. You may
faint and/or develop an infection with redness and irritation of the vein
at the site where blood is drawn. Frequent blood collection may cause
anemia (low red blood cell count), which may create a need for blood
transfusions.
This study may involve unpredictable risks to the participants.
Optional Procedures: You may experience pain, bleeding, and/or
bruising from the blood draws. You may faint and/or develop an
infection with redness and irritation of the vein at the site where blood
is drawn. Frequent blood collection may cause anemia (low red blood
cell count), which may create a need for blood transfusions.
Questionnaires may contain questions that are sensitive in nature.
You may refuse to answer any question that makes you feel
uncomfortable. If you have concerns after completing the
questionnaire, you are encouraged to contact your doctor or the study
chair.
5. POTENTIAL BENEFITS
Treatment on this study may help to control your symptoms.
Future patients may benefit from what is learned from this study.
There may be no benefits for you in this study.
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Optional Procedures: There are no benefits to you for taking part in
the optional procedure. Future patients may benefit from what is
learned.
6. ALTERNATE PROCEDURES OR TREATMENTS
You may choose not to take part in this study. You may chose to take
dexamethasone outside of this study. You may choose other
investigational therapy, if available. You may choose not to have
treatment for you symptoms of fatigue, pain, nausea, depression or
loss of appetite at all. Refusal to take part in this study will not cause
penalty or loss of benefits to which you are otherwise entitled.
Optional Procedures: Treatment with the study drug may be given
without taking part in the optional procedures.
I understand that the following statements about this study are
true:
7.

M. D. Anderson may benefit financially from my participation and/or
from what is learned in this study.

8.

This study is supported by: American Cancer Society (Mentored
Research Scholar Grant).

9.

I may ask the study chair any questions I have about this study,
including questions about the costs. I may contact the study chair, Dr.
Sriram Yennurajalingam, at 713-792-6085. I may also contact the
Chair of M. D. Anderson's IRB at 713-792-2933 with any questions
that have to do with this study or my rights as a study participant.

10. My participation in this research study is strictly voluntary. I may
refuse to take part in this study without any penalty or loss of benefits
to which I am otherwise entitled. I may also withdraw from
participation in this study at any time without any penalty or loss of
benefits. I should first discuss leaving the study with my doctor. If I
withdraw from this study, I may still be treated at M. D. Anderson.
11. I understand that the study may be changed or stopped at any time by
the study chair, American Cancer Society (Mentored Research
Scholar Grant), the U.S. Food and Drug Administration (FDA), the
Office for Human Research Protections (OHRP) (a regulatory agency
that oversees research in humans), or the IRB of M. D. Anderson.
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12. I will be informed of any new findings that might affect my willingness
to continue taking part in the study.
13. M. D. Anderson will take appropriate steps to keep my personal health
information private. However, there is no guarantee of absolute
privacy. Federal agencies (such as the FDA and the OHRP),
American Cancer Society (Mentored Research Scholar Grant), and
the IRB of M. D. Anderson might review my record to collect data or to
check that the research is being done safely and correctly. In some
situations, the FDA could be required to reveal the names of
participants.
14. If I suffer injury as a direct result of taking part in this study, M. D.
Anderson will provide medical care. However, this medical care will
be billed to my insurance provider or me in the ordinary manner. I
understand that I will not be reimbursed for expenses or compensated
financially by M. D. Anderson or American Cancer Society (Mentored
Research Scholar Grant) for this injury. I may also contact the Chair
of M. D. Anderson’s IRB at 713-792-2933 with questions about studyrelated injuries.
15. Certain tests, procedures, and/or medications that I may receive as
part of this study may be without cost to me because they are for
research purposes only. However, my insurance provider or I may be
financially responsible for the cost of supportive care and treatment of
any complications resulting from the research tests, procedures,
and/or medications, including hospitalization, nausea, vomiting, low
blood cell counts, and dehydration. Standard medical care that I
receive under this research study will be billed to my insurance
provider and/or me in the ordinary manner. I should learn before
taking part in this study which parts of the research-related care will
be provided without charge, which costs my insurance provider will
pay for, and which costs will be my responsibility. I may ask to speak
with a financial counselor about the costs of this study.
16. I understand that there are no plans to compensate me for any
patents or discoveries that may result from my participation in this
research. I will receive no compensation for taking part in this study.
Authorization for Use and Disclosure of Protected Health
Information:
A. During the course of this study, the research team at M. D. Anderson
will be collecting information about you. This information may include
your medical history, study schedule, and the results of any of your
tests, therapies, and/or procedures. The purpose of collecting and
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sharing this information is to learn about how the study procedures
may affect the disease and any study-related side effects. Your doctor
and the research team may share your study information with the
parties named in Section E below.
B. If you refuse to provide your authorization to disclose your protected
health information, you will not be able to participate in this research
study.
C. Your protected health information will be protected according to state
and federal law. However, there is no guarantee that your information
will remain confidential, and it may be re-disclosed at some point.
D. All identifying information such as your name and address will be kept
private. This information may be kept at M. D. Anderson forever. You
will be assigned a code number so that your name will not be used.
The research team at M. D. Anderson will be able to link the code
number to your name. In some instances, in order to ensure the
scientific value of the study, the parties named in Section E below will
be able to view your study record but will not be permitted to copy any
identifying information contained in your record.
E. Your information may be shared with the following parties:
American Cancer Society (Mentored Research Scholar Grant)
The FDA
The OHRP
The IRB of M. D. Anderson
Officials of M. D. Anderson
Clinical study monitors who verify the accuracy of the information
Individuals with medical backgrounds who determine the effect that
the study procedures may have on the disease
Individuals who put all the study information together in report form
F. You have the right to see and reproduce your records related to the
research study, and ask for corrections, for as long as this information
is held by the study chair and/or M. D. Anderson. However, in some
studies, in order to ensure the scientific value of the study,
participants are not able to view or reproduce their study records until
the research has been completed with all participants in the study. If
possible for this study, your doctor will be able to discuss your clinical
test results with you.
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G. There is no expiration date for the use of your protected health
information. You may withdraw your authorization to share your
protected health information at any time in writing. Instructions on
how to do this can be found in the M. D. Anderson Notice of Privacy
Practices (NPP). You may contact the IRB Staff at 713-792-2933 with
questions about how to find the NPP. If you withdraw your
authorization, you will be removed from the study and the study chair
and staff will no longer use or disclose your protected health
information in connection with this study, unless the study chair or
staff needs to use or disclose some of your research-related protected
health information to preserve the scientific value of the study. The
parties listed in Section E above may use any study data that were
collected before you canceled your authorization.
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CONSENT/PERMISSION/AUTHORIZATION
FOR TREATMENT AND OPTIONAL PROCEDURES
(Mark choice(s) with an "X")
I elect to ____ or not to ____ extra blood to be drawn as an optional
procedure.
Participant's Initials ________
I elect to ____ or not to ____ complete questionnaires as an optional
procedure.
Participant's Initials ________
I elect to ____ or not to ____ allow saliva to be collected as an optional
procedure.
Participant's Initials ________
Having read and understood the above and having had the chance to ask
questions about this study, think about the study, and talk with others as
needed, I give the study chair permission to enroll me on this study. By
signing this consent form, I am not giving up any of my legal rights. I have
been given a signed copy of this consent document.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF PARTICIPANT
DATE
I was present during the explanation of the research to be performed
under Protocol 2005-0816.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF WITNESS TO THE VERBAL CONSENT
PRESENTATION (OTHER THAN PHYSICIAN OR STUDY
CHAIR)

DATE

SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF PERSON RESPONSIBLE & RELATIONSHIP
DATE
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I have discussed this clinical research study with the participant and/or his
or her authorized representative, using language that is understandable
and appropriate. I believe that I have fully informed this participant of the
nature of this study and its possible benefits and risks and that the
participant understood this explanation.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
SIGNATURE OF STUDY CHAIR OR PERSON OBTAINING
CONSENT
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DATE

Translator
I have translated the above informed consent as written (without additions or
subtractions)
into _____________________________ and assisted the people
obtaining/providing
(Name of Language)
consent by translating all questions and responses during the consent
process for this participant.
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS
NAME OF TRANSLATOR

SIGNATURE OF TRANSLATOR

Please check here if the translator was a member of the research
team. (If checked, a witness, other than the translator, must sign the
witness line.)
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DATE

Appendix F:
Treatment Plan and Standard operating procedure:
This is a prospective, randomized double blind, placebo controlled study
comparing the effect of dexamethasone versus placebo. We will randomize 125
eligible patients to receive either dexamethasone 4 mg orally two times a day for
14 days or matching placebo. During the study period, patients will be assessed
for the intensity of fatigue, other symptoms and toxicities. Patients will also be
assessed by the research nurses for any signs and symptoms of infection while
on the study drug. Patients will undergo laboratory tests to measure cytokines.

A physician will do a physical exam on the patient on day 0, 15, and Day 29; If
patient is unable to return to clinic on Day 8, 15, 22, or 29 the assessments will
be done by the research nurse by phone. Laboratory correlates including
cytokine levels- IL-1, IL-6, IL-17 TNF-alpha, IL-10, IL-8, and corresponding
receptor levels, will be performed at baseline, Day 15 [ ± 3 days], and Day 29 [ ±
3 days. Patients will also be assessed by the research nurses for any signs and
symptoms of infection while on the study drug.

All study patients will be asked to return to the clinic for follow-up assessments 2
weeks after the study medication is discontinued ( day 43 ± 3 days) for a safety
and toxicity assessment. If the patient is unable to return to the clinic on day 43,
the safety and toxicity assessment will be done by the research nurse by
telephone
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